The Growing Global Market for E-Cigarettes

Nov.24.2022
The Growing Global Market for E-Cigarettes
The increasing social acceptance and demand for tobacco alternatives are expected to drive the e-cigarette market's 9.2% compound annual growth rate.

Several factors, such as the increasing social acceptance of electronic cigarettes, the continuous improvement of electronic cigarette devices, the surging demand for tobacco cigarette alternatives, rapid technological advancements, and ongoing product innovation, are expected to drive the development of the electronic cigarette market, with a projected compound annual growth rate of 9.2% for the forecast period of 2020-2030. According to data from P&S Intelligence, market revenues are expected to increase from $15.7 billion in 2019 to $39 billion by 2030. In recent years, the expanding range of flavors has become a major market trend.


Today, the increasing acceptance of electronic cigarettes is driving demand for their products, as they do not release toxic substances. Because tobacco-based cigarettes emit smoke, some governments have taken multiple measures to ban smoking in certain public places. Through these bans, governments aim to create a greener and more sustainable environment. Additionally, increasing public awareness of environmental and human health concerns is likely to drive global demand for electronic cigarettes.


In addition, the widespread availability of e-cigarettes through various distribution channels is expected to fuel global growth in the e-cigarette market. Currently, e-cigarette manufacturers sell and promote their products through dedicated stores, kiosks in grocery and retail stores, and outlet centers that offer e-cigarette experiences similar to those of clubs. These stores are seeing an influx of traditional smokers who can use a variety of flavors and e-cigarette products. The e-cigarette market is segmented by age group: 16-24, 25-34, 35-44, 45-54, 55-65, and 65+. In this market, the 16-24 age group had the largest market share in 2019, as modular e-cigarettes designed for young people became popular. Market participants are designing social media campaigns, such as #JUULing, to target this tech-savvy demographic. Currently, e-cigarette market participants are focused on product launches to stay ahead of competitors. For example, in March 2019, Japan Tobacco Inc. released two new flavors of tobacco capsules for its Ploom TECH brand: Pianissimo Aria Menthol and Pianissimo Pineapple Peach Yellow Cooler. Other market participants tracking these strategic moves include British American Tobacco, MCIG Inc., FIN Branding Group LLC, MadVapes LLC, Philip Morris International Inc., Shenzhen iSmoka Electronics Co. Ltd., Altria Group Inc., Smoker Friendly International LLC, and Innokin Technology Co. Ltd.


According to regional analysis, Europe held the largest share of the e-cigarette market in 2019, with the UK, Netherlands, Germany, Spain and Italy generating the highest revenue. This can be attributed to the increasing popularity of e-cigarette shop culture in the region. Looking ahead, the North American market is expected to experience rapid growth due to declining popularity of traditional cigarettes and the increasing prevalence of e-cigarette products among young Americans. This is expected to drive market growth.


Statement:


This article is compiled from third-party information for industry communication and learning purposes only.


The views expressed in this article do not reflect the opinions of 2FIRSTS and we are unable to confirm the accuracy and authenticity of its content. This article has been compiled for the sole purpose of industry discussion and research.


Due to limitations in translation abilities, the translated article may not accurately convey the same expression as the original text. Therefore, please refer to the original text for accuracy.


2FIRSTS is fully in line with the Chinese government's statements and positions on any domestic, Hong Kong, Macao, Taiwan, or international issues.


The compilation of information is the property of the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia's new retail tobacco permit system took effect October 1, requiring sellers of vapes, nicotine products and related devices and accessories to obtain a Retail Tobacco Permit for each business location. Virginia ABC said more than 3,000 businesses applied in September alone, creating a processing backlog. Qualifying applicants that filed before October 1 may temporarily operate under a Letter of Authorization. The new store-level permit also sits alongside Virginia's existing vape product directory, where sales of unlisted liquid nicotine or nicotine vapor products can trigger civil penalties starting at $5,000.
Regulations
Oct.03
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives